سیاه‌زخم: تاریخ، زیست‌شناسی، توزیع جهانی، جنبه‌های بالینی، ایمنی‌شناسی و زیست‌شناسی مولکولی

Following the post 9/11 distribution of anthrax spores through the U.S. mail, and the resulting deaths of five individuals - primarily due to initial misdiagnosis - there has been a renewed interest in anthrax among clinicians and intelligence agencies, particularly as a biological warfare agent. This monograph brings forth essential knowledge about anthrax. Included in this volume, are, the early history, non-natural outbreaks of anthrax, characteristics of the causative organism Bacillus anthracis and its relationship to other members of the B. cereus family. Also included are reports on extensive clinical findings, mechanisms of anthrax virulence and the genetics responsible for these virulence factors. The extensive studies over the years regarding the development of veterinary and human vaccines, and molecular studies, including conventional PCR and real-time PCR are explained in comprehensive detail, with the help of tables, figures and extensive references. This eBook serves as an advanced presentation and reference work for individuals seeking detailed information regarding anthrax and as a primary guide for individuals pursuing studies on anthrax. Frontiers in Clinical Drug Research—Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases—diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research—Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The first volume of this series features 6 chapters that cover a variety of topics including: Angiotensin blockers Agents targeting advanced glycation end products Drugs and the peroxisome proliferator activated receptors Topical Drugs for diabetic complications Research on Liraglutide Research on MicroRNAs as agents for diabetes treatment